Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Favezelimab - Merck Sharp & Dohme

Next Previous
Drug Profile

Favezelimab - Merck Sharp & Dohme

Alternative Names: Mavezelimab - Merck Sharp & Dohme; MK-4280

Latest Information Update: 30 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haematological malignancies; Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 25 Jul 2024 Phase-I/II clinical trials are ongoing in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, In neonates, In infants, In children, In adolescents) in South Korea (IV) (NCT06395090)
  • 25 Jul 2024 Phase-I/II clinical trials in Haematological malignancies (Late-stage disease, Second-line therapy or greater, Combination therapy, In neonates, In infants, In children, In adolescents) in South Korea (IV) (NCT06395090)
  • 13 Jun 2024 Efficacy and adverse events data from a phase I/II trial in Haematological malignancies presented at the 29th Congress of the European Haematology Association (EHA-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top